Symbols / INAB Stock $1.40 -3.45% IN8bio, Inc.

Healthcare • Biotechnology • United States • NCM
INAB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Tai-Wei Ho
Exch · Country NCM · United States
Market Cap 13.43M
Enterprise Value -5.31M
Income -18.98M
Sales —
FCF (ttm) -7.13M
Book/sh 2.31
Cash/sh 2.23
Employees 17
Insider 10d —
IPO Jul 30, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -1.32
PEG —
P/S —
P/B 0.61
P/C —
EV/EBITDA 0.30
EV/Sales —
Quick Ratio 10.17
Current Ratio 10.50
Debt/Eq 10.33
LT Debt/Eq —
EPS (ttm) -2.54
EPS next Y -1.06
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-07
Earnings (prior) 2026-05-07
ROA -52.75%
ROE -103.55%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 9.59M
Shs Float 7.03M
Insider Own 13.40%
Instit Own 38.12%
Short Float 1.22%
Short Ratio 1.59
Short Interest 107.42K
52W High 2.90
vs 52W High -51.64%
52W Low 1.17
vs 52W Low 19.66%
Beta —
Impl. Vol. —
Rel Volume 0.52
Avg Volume 72.80K
Volume 37.66K
Target (mean) $6.25
Tgt Median $5.50
Tgt Low $4.00
Tgt High $10.00
# Analysts 4
Recom Strong_buy
Prev Close $1.45
Price $1.40
Change -3.45%
About

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.25
Mean price target
2. Current target
$1.40
Latest analyst target
3. DCF / Fair value
$-13.38
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.40
Low
$4.00
High
$10.00
Mean
$6.25

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-13 reit HC Wainwright & Co. Buy → Buy $6
2025-03-14 main HC Wainwright & Co. Buy → Buy $6
2025-02-12 reit HC Wainwright & Co. Buy → Buy $8
2025-02-11 up Jones Trading Hold → Buy $1
2024-11-26 reit HC Wainwright & Co. Buy → Buy $8
2024-11-13 main HC Wainwright & Co. Buy → Buy $8
2024-08-12 down Jones Trading Buy → Hold —
2024-06-14 main Jones Trading Buy → Buy $7
2024-06-14 reit HC Wainwright & Co. Buy → Buy $13
2024-06-04 reit HC Wainwright & Co. Buy → Buy $13
2024-05-13 main HC Wainwright & Co. Buy → Buy $13
2024-04-10 reit HC Wainwright & Co. Buy → Buy $14
2024-03-18 init Laidlaw & Co. — → Buy $8
2024-03-15 reit HC Wainwright & Co. Buy → Buy $14
2024-03-13 init JonesTrading — → Buy $5
2023-11-13 reit HC Wainwright & Co. Buy → Buy $14
2023-08-11 reit HC Wainwright & Co. Buy → Buy $14
2023-06-05 reit EF Hutton Buy → Buy $8
2023-05-16 reit HC Wainwright & Co. Buy → Buy $14
2023-04-26 reit HC Wainwright & Co. — → Buy $14
News
RSS: Latest INAB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-05-27 FAIRBAIRN EMILY WANG Director — 724,637 $0.00 $0
2025-12-22 FAIRBAIRN EMILY WANG Director — 724,637 $1.38 $999,999
2025-12-22 BRANDT PETER C Director — 72,464 $1.38 $100,000
2025-12-22 ROEMER ALAN S. Director — 36,232 $1.38 $50,000
2025-12-22 HO WILLIAM TAI WEI Chief Executive Officer — 36,232 $1.38 $50,000
2025-12-22 MCCALL PATRICK CPA Chief Financial Officer — 7,247 $1.38 $10,001
2025-12-22 ROCHLIN KATE PH.D. Chief Operating Officer — 7,247 $1.38 $10,001
2025-04-30 BRANDT PETER C Director — 163,934 $0.18 $30,229
2025-04-30 ROEMER ALAN S. Director — 113,459 $0.18 $20,922
2025-04-30 MCCALL PATRICK CPA Chief Financial Officer — 15,000 $0.18 $2,766
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
19.86
-32.90%
29.60
-1.36%
30.01
+5.21%
28.52
Research And Development
10.21
-39.80%
16.96
+0.80%
16.83
+19.66%
14.06
Selling General And Administration
9.65
-23.64%
12.64
-6.46%
13.51
-6.56%
14.46
General And Administrative Expense
9.65
-23.64%
12.64
-6.46%
13.51
-6.56%
14.46
Other Gand A
9.65
-23.64%
12.64
-6.46%
13.51
-6.56%
14.46
Other Operating Expenses
—
—
-0.33
—
Total Expenses
19.86
-32.90%
29.60
-1.36%
30.01
+5.21%
28.52
Operating Income
-19.86
+32.90%
-29.60
+1.36%
-30.01
-5.21%
-28.52
Total Operating Income As Reported
-19.44
+36.13%
-30.44
-1.43%
-30.01
-5.21%
-28.52
EBITDA
-17.36
+35.57%
-26.94
+2.04%
-27.51
-0.32%
-27.42
Normalized EBITDA
-17.36
+32.91%
-25.88
+5.93%
-27.51
-0.32%
-27.42
Reconciled Depreciation
2.50
-5.80%
2.65
+6.16%
2.50
+126.75%
1.10
EBIT
-19.86
+32.90%
-29.60
+1.36%
-30.01
-5.21%
-28.52
Total Unusual Items
0.00
+100.00%
-1.07
0.00
—
Total Unusual Items Excluding Goodwill
0.00
+100.00%
-1.07
0.00
—
Special Income Charges
0.00
+100.00%
-1.07
0.00
—
Restructuring And Mergern Acquisition
0.00
-100.00%
1.07
0.00
—
Net Income
-19.44
+36.13%
-30.44
-1.43%
-30.01
-5.21%
-28.52
Pretax Income
-19.44
+36.13%
-30.44
-1.43%
-30.01
-5.21%
-28.52
Net Non Operating Interest Income Expense
0.42
+83.04%
0.23
0.00
—
Net Interest Income
0.42
+83.04%
0.23
0.00
—
Interest Income Non Operating
0.42
+83.04%
0.23
0.00
—
Interest Income
0.42
+83.04%
0.23
0.00
—
Other Income Expense
—
-1.07
-423.64%
0.33
—
Other Non Operating Income Expenses
—
—
0.33
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-19.44
+36.13%
-30.44
-1.43%
-30.01
-5.21%
-28.52
Net Income From Continuing Operation Net Minority Interest
-19.44
+36.13%
-30.44
-1.43%
-30.01
-5.21%
-28.52
Net Income From Continuing And Discontinued Operation
-19.44
+36.13%
-30.44
-1.43%
-30.01
-5.21%
-28.52
Net Income Continuous Operations
-19.44
+36.13%
-30.44
-1.43%
-30.01
-5.21%
-28.52
Normalized Income
-19.44
+33.81%
-29.37
+2.13%
-30.01
-5.21%
-28.52
Net Income Common Stockholders
-19.44
+36.13%
-30.44
-1.43%
-30.01
-5.21%
-28.52
Diluted EPS
-4.44
+73.96%
-17.05
+43.17%
-30.00
+26.47%
-40.80
Basic EPS
-4.44
+73.96%
-17.05
+43.17%
-30.00
+26.47%
-40.80
Basic Average Shares
4.37
+145.08%
1.78
+79.30%
1.00
+42.43%
0.70
Diluted Average Shares
4.37
+145.08%
1.78
+79.30%
1.00
+42.43%
0.70
Diluted NI Availto Com Stockholders
-19.44
+36.13%
-30.44
-1.43%
-30.01
-5.21%
-28.52
Line Item Trend 2023-12-31
Total Assets
33.71
Current Assets
24.62
Cash Cash Equivalents And Short Term Investments
21.28
Cash And Cash Equivalents
21.28
Cash Financial
21.28
Prepaid Assets
3.07
Other Current Assets
0.27
Total Non Current Assets
9.08
Net PPE
8.57
Gross PPE
9.86
Accumulated Depreciation
-1.28
Properties
0.00
Machinery Furniture Equipment
0.88
Construction In Progress
0.18
Other Properties
4.88
Leases
3.92
Goodwill And Other Intangible Assets
—
Other Intangible Assets
—
Non Current Deferred Assets
—
Other Non Current Assets
0.51
Total Liabilities Net Minority Interest
8.77
Current Liabilities
5.39
Payables And Accrued Expenses
2.21
Payables
0.92
Accounts Payable
0.92
Current Accrued Expenses
1.28
Pensionand Other Post Retirement Benefit Plans Current
1.67
Current Debt And Capital Lease Obligation
1.51
Current Capital Lease Obligation
1.51
Total Non Current Liabilities Net Minority Interest
3.38
Long Term Debt And Capital Lease Obligation
3.38
Long Term Capital Lease Obligation
3.38
Non Current Deferred Liabilities
—
Stockholders Equity
24.94
Common Stock Equity
24.94
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
1.44
Ordinary Shares Number
1.44
Treasury Shares Number
0.00
Additional Paid In Capital
116.15
Retained Earnings
-91.22
Total Equity Gross Minority Interest
24.94
Total Capitalization
24.94
Working Capital
19.23
Invested Capital
24.94
Total Debt
4.89
Capital Lease Obligations
4.89
Net Tangible Assets
24.94
Tangible Book Value
24.94
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-12.71
+47.36%
-24.15
-3.47%
-23.34
+3.24%
-24.12
Cash Flow From Continuing Operating Activities
-12.71
+47.36%
-24.15
-3.47%
-23.34
+3.24%
-24.12
Net Income From Continuing Operations
-19.44
+36.13%
-30.44
-1.43%
-30.01
-5.21%
-28.52
Depreciation Amortization Depletion
2.50
-5.80%
2.65
+6.16%
2.50
+126.75%
1.10
Depreciation
2.50
-5.80%
2.65
+6.16%
2.50
+126.75%
1.10
Depreciation And Amortization
2.50
-5.80%
2.65
+6.16%
2.50
+126.75%
1.10
Stock Based Compensation
3.19
-36.22%
5.00
+14.42%
4.37
+26.05%
3.47
Operating Gains Losses
—
0.04
—
—
Gain Loss On Sale Of PPE
0.00
-100.00%
0.04
0.00
—
Change In Working Capital
1.04
+173.51%
-1.41
-592.16%
-0.20
-20.00%
-0.17
Change In Prepaid Assets
0.67
-64.53%
1.89
+174.17%
0.69
+132.92%
-2.09
Change In Payables And Accrued Expense
0.51
+120.71%
-2.44
-1220.54%
-0.18
-107.60%
2.43
Change In Accrued Expense
0.59
+130.71%
-1.91
-339.70%
0.80
-13.85%
0.92
Change In Payable
-0.08
+85.05%
-0.54
+45.46%
-0.98
-164.97%
1.51
Change In Account Payable
-0.08
+85.05%
-0.54
+45.46%
-0.98
-164.97%
1.51
Change In Other Current Assets
0.13
+745.00%
-0.02
0.00
+100.00%
-0.10
Change In Other Current Liabilities
-0.27
+68.14%
-0.84
-18.36%
-0.71
-71.01%
-0.41
Investing Cash Flow
0.00
+100.00%
-0.19
+68.83%
-0.60
+83.81%
-3.71
Cash Flow From Continuing Investing Activities
0.00
+100.00%
-0.19
+68.83%
-0.60
+83.81%
-3.71
Net PPE Purchase And Sale
0.00
+100.00%
-0.19
+68.83%
-0.60
+83.81%
-3.71
Purchase Of PPE
0.00
+100.00%
-0.19
+68.83%
-0.60
+83.81%
-3.71
Capital Expenditure
—
-0.19
+68.83%
-0.60
+83.81%
-3.71
Financing Cash Flow
28.64
+101.90%
14.18
-47.55%
27.04
+200.89%
8.99
Cash Flow From Continuing Financing Activities
28.64
+101.90%
14.18
-47.55%
27.04
+200.89%
8.99
Net Issuance Payments Of Debt
-0.69
+12.72%
-0.79
+0.50%
-0.80
-29.76%
-0.61
Issuance Of Debt
—
—
—
—
Repayment Of Debt
-0.69
+12.72%
-0.79
+0.50%
-0.80
-29.76%
-0.61
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
-0.69
+12.72%
-0.79
+0.50%
-0.80
-29.76%
-0.61
Net Long Term Debt Issuance
-0.69
+12.72%
-0.79
+0.50%
-0.80
-29.76%
-0.61
Short Term Debt Payments
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
27.07
+172.22%
9.94
-59.52%
24.56
+157.43%
9.54
Proceeds From Stock Option Exercised
2.26
-55.82%
5.12
+56.31%
3.28
+5273.77%
0.06
Net Other Financing Charges
—
-0.09
—
—
Changes In Cash
15.93
+256.88%
-10.15
-427.06%
3.10
+116.26%
-19.09
Beginning Cash Position
11.39
-47.14%
21.54
+16.84%
18.43
-50.54%
37.27
End Cash Position
27.09
+143.63%
11.12
-47.75%
21.28
+17.05%
18.18
Free Cash Flow
-12.71
+47.76%
-24.34
-1.65%
-23.94
+13.97%
-27.83
Common Stock Issuance
27.07
+172.22%
9.94
-59.52%
24.56
+157.43%
9.54
Issuance Of Capital Stock
27.07
+172.22%
9.94
-59.52%
24.56
+157.43%
9.54
Net Preferred Stock Issuance
—
—
—
—
Other Cash Adjustment Outside Changein Cash
-0.22
+17.29%
-0.27
-3.91%
-0.26
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category